Literature DB >> 8212858

The HSV-1 UL45 18 kDa gene product is a true late protein and a component of the virion.

R J Visalli1, C R Brandt.   

Abstract

Previously we constructed a null mutation in the HSV-1 UL45 gene, showed that the UL45 gene was not required for growth in Vero cells, and confirmed that it coded for an 18 kDa protein (R.J. Visalli and C.R. Brandt, Virology 185:419-423, 1991). In this study, we have continued our characterization of the UL45 gene and the 18 kDa protein. Analysis of UL45 RNA revealed that the gene was expressed late and was inhibited in the presence of phosphonoacetic acid (paa), indicating it is a gamma 2 class gene. Using a specific polyclonal antiserum, we found that the 18 kDa UL45 gene product was also expressed late and was inhibited in the presence of paa. The 18 kDa protein was present in purified virions and was substantially enriched in the envelope-tegument fraction of virions disrupted with NP-40 detergent. The 18 kDa protein is thus a structural protein of the virus and appears to be associated with the viral envelope. A 20 kDa protein that cross-reacted with a polyclonal HSV-1 UL45 antiserum was also detected in cells infected with HSV-2 strain 333.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212858     DOI: 10.1016/0168-1702(93)90057-t

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  19 in total

1.  Contributions of herpes simplex virus 1 envelope proteins to entry by endocytosis.

Authors:  Tri Komala Sari; Suzanne M Pritchard; Cristina W Cunha; George A Wudiri; Elizabeth I Laws; Hector C Aguilar; Naomi S Taus; Anthony V Nicola
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

2.  The virion host shutoff protein of herpes simplex virus type 1: messenger ribonucleolytic activity in vitro.

Authors:  B D Zelus; R S Stewart; J Ross
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  Herpes simplex virus 2 UL45 is a type II membrane protein.

Authors:  A S Cockrell; M I Muggeridge
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.

Authors:  Inna V Larsen; Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-28       Impact factor: 2.671

5.  Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.

Authors:  Marianne Berdugo; Inna V Larsen; Claire Abadie; Catherine Deloche; Laura Kowalczuk; Elodie Touchard; Richard Dubielzig; Curtis R Brandt; Francine Behar-Cohen; Jean-Marc Combette
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

6.  Reversible conformational change in herpes simplex virus glycoprotein B with fusion-from-without activity is triggered by mildly acidic pH.

Authors:  Carlos R Siekavizza-Robles; Stephen J Dollery; Anthony V Nicola
Journal:  Virol J       Date:  2010-12-01       Impact factor: 4.099

7.  Role of the UL45 protein in herpes simplex virus entry via low pH-dependent endocytosis and its relationship to the conformation and function of glycoprotein B.

Authors:  Stephen J Dollery; Kristin D Lane; Mark G Delboy; Devin G Roller; Anthony V Nicola
Journal:  Virus Res       Date:  2010-01-18       Impact factor: 3.303

8.  Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Authors:  Monica M Sauter; Joshua J L Gauger; Curtis R Brandt
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

9.  Transactivation of a viral target gene by herpes simplex virus ICP27 is posttranscriptional and does not require the endogenous promoter or polyadenylation site.

Authors:  Keith D Perkins; Jennifer Gregonis; Sarah Borge; Stephen A Rice
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  The UL45 gene product is required for herpes simplex virus type 1 glycoprotein B-induced fusion.

Authors:  E J Haanes; C M Nelson; C L Soule; J L Goodman
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.